Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

(RTTNews) - Foster City, California-based Gilead Sciences, Inc. is recalling one lot of Veklury (remdesivir) for Injection 100 mg/vial for treating COVID-19, to the consumer level, due to the ...

Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Gilead Sciences has issued a voluntary recall of one lot of COVID-19 antiviral Veklury, also known as remdesivir, after confirming "the presence of a glass particle" in a vial. A customer ...

BTN estimates Gilead spent $100 million on U.S.-booked air volume in 2023, up from the prior year. The biopharmaceutical company, which specializes in HIV/AIDS and other antiviral drugs, turned around ...

The U.S. Food and Drug Administration had granted accelerated approval to Trodelvy for previously treated patients with ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...